Skip to main content

Advertisement

Table 3 Crude incidence rates of malignancies

From: Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT

  n of CA n pyrs IR
Characteristics at baseline     
Age (per 10 yrs increase)     
Female 52 3,917 9,687 5.4
Male 22 1,081 2,554 8.6
Co-morbid conditions:     
COPD     
No 63 4,754 11,677 5.4
Yes 11 244 564 19.5
Gastrointestinal disease     
No 61 4,579 11,153 5.5
Yes 13 419 1,088 11.9
Renal disease     
No 70 4,835 11,884 5.9
Yes 4 163 357 11.2
Characteristics at follow-up     
DAS28     
   <3.2 6 787 2,165 2.8
   3.2 to 5.1 34 2,823 7,341 4.6
   >5.1 34 1,388 2,735 12.4
Ever exposed to     
Conventional DMARDs only 30 1,684 # 3,561 8.4
Anti-TNF agents 44 3,651 * 8,558 5.1
Anakinra 5 247 $ 690 7.2
  1. CA: malignancies, n = number of cases, pyrs = follow-up time in patient years, IR = crude incidence rate per 1,000 pyrs.
  2. #35 of the patients in the DMARD cohort were exposed to anti-TNF agents before inclusion in the study. According to the ever exposed approach their follow-up time was assigned to the anti-TNF treated group.
  3. * Patients included in this group are patients who were included in the study with the start of an anti-TNF agent (n = 3,201) and patients who changed during follow-up from DMARD or anakinra treatment to anti-TNF treatment
  4. $223 of the 247 pts were exposed to anakinra and anti-TNF agents, they experienced five malignancies.